PHARMAQ Analytiq announces the opening of a new laboratory to enhance aquaculture diagnostic capabilities in Scotland

Picture: from left to right - Angela Ashby, Head of Clinical Services, PHARMAQ Analytiq Scotland, Ruaraidh MacNeil, Director of Business Infrastructure, Highlands and Islands Enterprise and Chris Matthews, Business Unit Director UK & Ireland, PHARMAQ Analytiq Scotland.

PRESS RELEASE

PHARMAQ Analytiq announces the opening of a new laboratory to enhance aquaculture diagnostic capabilities in Scotland

Aquaculture Health and Environmental Leader to Open New Molecular Diagnostic Laboratory at the Inverness Campus

INVERNESS, SCOTLAND, (8th February 2022)   Following from the acquisition of Fish Vet Group last year, PHARMAQ Analytiq Scotland announce the opening of a dedicated molecular biology laboratory at Solasta House on Inverness Campus.

The new laboratory complements the existing digital pathology, microbiology and environmental laboratories already in Inverness and will deliver faster results to Scottish farms using PCR to safeguard the health of fish populations.

Chris Matthews, PHARMAQ Analytiq’s Business Unit Director in the UK and Ireland explained “Raising healthy fish to meet the demands of our growing global population while respecting the environment is critical for a healthier, more sustainable future. Innovative fish health management tools, across the continuum of care and including vaccines and diagnostic testing, will help us better meet the needs of our customers. We are excited to strengthen our diagnostic operations in Scotland.  This new opening will create three new highly skilled positions in Inverness and deliver an improved service for our customers worldwide. High quality, rapid molecular techniques including PCR are at the centre of preventative health work in aquaculture but are also now finding application in how we monitor the surrounding environment or even the resilience of farms against the effects of climate change.”

“This investment marks the beginning of a new and exciting period for our operations in Scotland,” said Nils Arne Grønlie, General Manager of PHARMAQ Analytiq. “The laboratory completes the range of services delivered entirely in-country, and we intend now to further develop our infrastructure in Inverness.”

“The heart of our business will always be the veterinary diagnosticians, pathologists and scientists which make up our team,” Grønlie adds.  “Yet monitoring the health of fish and their environment will look different in ten years and together with R&D colleagues at Zoetis we are at work on the next generation of monitoring tools which will further evolve how preventative health programmes are approached in Scotland and elsewhere.”

The new laboratory is situated on Inverness Campus, developed by Highlands and Islands Enterprise (HIE) and opened in 2015 as a world-class location for the life sciences and technology sectors and which represents a growing hub for aquaculture service, research and development activity. Ruaraidh MacNeil, Director of Business Infrastructure for the Campus, remarked “we are delighted to welcome PHARMAQ Analytiq, part of the world’s largest animal health company -Zoetis on to the Campus. Human and animal health including aquaculture are key focuses for activity at the Campus. Inverness has long been an important centre for the aquaculture industry, but the location of PHARMAQ Analytiq alongside the organisations already on-site working in the sector and the collaborative possibilities this brings is truly exciting.”

Inverness Campus is home to a range of businesses as well as the University of the Highlands and Islands (UHI), the Rivers and Loch Institute and Scotland’s Rural College (SRUC). SRUC recently lodged a formal planning applications for of a new £7m data-driven innovation centre for veterinary science at Inverness campus.

About PHARMAQ part of Zoetis

PHARMAQ is the global leader in fish health and vaccines, dedicated to support sustainable growth in the aquaculture industry. PHARMAQ is part of Zoetis, the world leader in animal health. Our innovative fish health solutions include PHARMAQ fish vaccines and therapeutics, PHARMAQ Fishteq vaccination machinery, and PHARMAQ Analytiq research and analysis. PHARMAQ’s research and production facilities are based in Norway, with global operations in commercial fish farming markets. PHARMAQ has 375 employees. To learn more, visit PHARMAQ.com

About PHARMAQ Analytiq

PHARMAQ Analytiq is part of PHARMAQ and with its around 100 talented and dedicated colleagues it represents the world’s largest provider of dedicated evidence-based veterinary diagnostics, consultancy and environmental monitoring to the aquaculture sector. PHARMAQ Analytiq is dedicated to supporting sustainable growth in global aquaculture and in addition to its headquarters and laboratory in Bergen (Norway), it provides services from operations in Oslo (Norway), Rørvik (Norway), Inverness (Scotland), Galway (Ireland), and Puerto Montt (Chile) For more information, visit: https://www.pharmaq.com/en/analytiq

About Zoetis

As the world’s leading animal health company, Zoetis exists to nurture our world and humankind by advancing care for animals. With nearly 70 years of experience innovating a leading portfolio and pipeline of medicines, vaccines, diagnostics, and therapeutic technologies, Zoetis stands by those caring for animals by providing solutions worldwide.

Forward-looking Information

This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to business plans or prospects, future operating or financial performance, future guidance, future operating models, expectations regarding products, expectations regarding the performance of acquired companies and our ability to integrate new businesses, expectations regarding the financial impact of acquisitions, future use of cash and dividend payments, and other future events.

These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.

© 2022 Zoetis Services LLC. All rights reserved.